{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.5","value":"1.94"},{"groupId":"OG001","spread":"29.8","value":"1.97"},{"groupId":"OG002","spread":"24.9","value":"3.87"},{"groupId":"OG003","spread":"60.2","value":"2.73"},{"groupId":"OG004","spread":"61.2","value":"3.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"59"},{"groupId":"OG004","value":"18"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 40 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG000","title":"Part 1: 40 mg QD"},{"description":"Participants received 80 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG001","title":"Part 1: 80 mg QD"},{"description":"Participants received 160 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG002","title":"Part 1: 160 mg QD"},{"description":"Part 1: Participants received 160 mg of zanubrutinib twice daily (BID) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up. Part 2: This dose regimen was selected for further evaluation in various expansion cohorts that span multiple disease types.","id":"OG003","title":"Part 1 and Part 2: 160 mg BID"},{"description":"Part 1: Participants received 320 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up. Part 2: This dose regimen was selected for further evaluation in various expansion cohorts that span multiple disease types.","id":"OG004","title":"Part 1 and Part 2: 320 mg QD"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included all participants for whom valid zanubrutinib PK parameters could be estimated, shown as overall number analyzed. Only participants with available data per dose were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours","title":"Part 1 and Part 2: Apparent Terminal Half-life (t1/2) of Zanubrutinib","type":"SECONDARY","unitOfMeasure":"Hours"}